Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Broad Scientists Launch Biotech

by Lisa M. Jarvis
January 12, 2009 | A version of this story appeared in Volume 87, Issue 2

Three scientists from the Broad Institute of MIT and Harvard University—Stuart L. Schreiber, Todd R. Golub, and Michael A. Foley—have joined forces to launch Forma Therapeutics, a drug firm focused on discovering drugs that act against challenging cancer targets. Cambridge, Mass.-based Forma will employ a cell-based screening platform to identify targets and will then apply structure-based drug discovery methods to design and optimize molecules to interact with those targets. The start-up has received $25 million in funding from the Novartis Option Fund, the investment arm of the Swiss drug giant, and Bio*One Capital, of Singapore.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.